Frequent Skin Cancers May Signal Risk of Others
For the study, the researchers analyzed the DNA of 61 patients with frequent basal cell carcinomas, and found 20 percent had mutations in genes that help repair DNA damage in body cells. Cancer arises when such abnormal cells grow and spread unchecked.
Conclusions: The olaparib and carboplatin combination is tolerable and has clinical benefit in subsets of heavily pretreated BRCAwt HGSOC, independent of platinum sensitivity. PMID: 31080557 [PubMed]
In conclusion, we identified high genomic instability in LARC, which was related to alterations in the HR pathway, especially in pIR. These findings suggest that patients with impaired HRD would clinically benefit from PARP-inhibitors and platinum-based therapy.
Authors: Davidson B Abstract INTRODUCTION: Ovarian cancer, consisting predominantly of ovarian carcinoma, is the most lethal gynecologic malignancy. Diagnosis at the advanced stage, particularly in high-grade serous carcinoma which is the most common and clinically aggressive histotype, is a major factor negatively affecting survival, while tumor heterogeneity and chemoresistance often preclude complete elimination of tumor cells even following radical surgery and combination chemotherapy. Recently, inhibition of angiogenesis and inhibition of poly (ADP-ribose) polymerase (PARP) have shown benefit in the treatment ...
In the past few blogs, I've been discussing the recent publication of my book,Evolution ’s Clinical Guidebook: Translating Ancient Genes Into Precision Medicine. The premise of this book is that modern medicine is based on an understanding of evolutionary processes. Evolution shows us the relationships between the subdisciplines of medicine that benefit directly from Precision Medicine (i.e., pathology, microbiology, clinical genetics, pharmacology, and bioinformatics). In Evolution's Clinical Guidebook, all of these diverse fields are brought together, under the subject of evolution. To illustrate, I have listed bel...
ConclusionDNA repair gene XRCC3 polymorphism rs 861539 T allele and the rs 861539 T/rs 1799794 A haplotype may boost the susceptibility to ovarian carcinoma with no correlation with the tumor histological subtypes and stages. They may be salutary as a DNA-based diagnostic biomarker for identifying the high-risk Egyptian females susceptible to ovarian cancer. More studies are needed to clarify the underlying mechanisms that can contribute to ovarian cancer, assess the cancer prognosis, and help to determine adequate therapy regimen.
CONCLUSION: Powerful delivery systems for reproduced p53 expression and activation in cancer cells would be a promising treatment to achieve therapeutic goal for HNSCC. PMID: 31074365 [PubMed - as supplied by publisher]
CONCLUSIONS: The landscape of DDR mutations and their association with genetic and clinicopathological features demonstrated that PLC patients with altered DDR genes may be rational candidates for precision oncology treatment. PMID: 31068370 [PubMed - as supplied by publisher]
ConclusionsThese two cases suggest that indels might be a new predictor of PD-1 blockade response for ICC patients beside PD-L1 expression, TMB, MSI, and dMMR, warranting further clinical investigation.
Abstract Epithelial-to-mesenchymal transition (EMT) and its reversed process, mesenchymal-to-epithelial transition (MET), are fundamental processes in embryonic development and tissue repair but confer malignant properties to carcinoma cells, including invasive behavior, cancer stem cell activity, and greater resistance to chemotherapy and immunotherapy. Understanding the molecular and cellular basis of EMT provides fundamental insights into the etiology of cancer and may, in the long run, lead to new therapeutic strategies. Here, we discuss the regulatory mechanisms and pathological roles of epithelial-mesenchyma...
Conclusions: These findings confirm the involvement of H3K4 specific demethylases in the response to DNA damage, show a requirement of the catalytic function and suggest new strategies for the therapeutic use of their inhibitors.